

Special Issue

Novel Adjuvants and Delivery Systems for Vaccines

Message from the Guest Editors

Novel adjuvants and delivery systems for vaccines improve the quality of vaccine production by enhancing the immune response to a vaccine. Adjuvants can strengthen the immune system's response to the vaccine. Adjuvants have been traditionally used to increase the magnitude of the antibody response to a vaccine based on antibody titer or the ability to prevent infection and can guide the type of adaptive response to produce the most effective form of immunity. It is important to consider the construction of vaccine adjuvant delivery systems for both adjuvant activity and antigen delivery. In this Special Issue, we will explore prospective novel adjuvant approaches to modify innate and adaptive immune responses to ease the development of enhanced prophylactic or therapeutic vaccines. We welcome contributions to vaccine adjuvant advances, immune enhancement mechanisms, rational design, immunostimulatory molecules, emulsions, liposomes, virosomes, and polymers with functional molecules.

Guest Editors

Dr. Christiane Chbib

Department of Pharmaceutical Sciences, Larkin University, Miami, FL 33169, USA

Dr. Mohammad N. Uddin

Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/203343

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).